Pharmaceutical Technology3 天
DVX-201 by Coeptis Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
DVX-201 is under clinical development by Coeptis Therapeutics and currently in Phase I for Myelodysplastic Syndrome.
Cure Today6 天
A Commitment to New Therapies for MPN Despite Scientific Challenges
One research noted the persistent efforts to develop new treatments for myeloproliferative neoplasms (MPNs), a commitment ...